The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes ...
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers ...
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers ...
A study at Rutgers University found the medications may be connected to a higher likelihood of ischemic optic neuropathy.
The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes ...
Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and ...
Novo Nordisk sued Eli Lilly, alleging misleading ads unfairly compare doses of Zepbound and Mounjaro with Wegovy and Ozempic.
Finerenone plus empagliflozin combination therapy reduces systolic blood pressure in patients with T2D and chronic kidney disease.
An FDA advisory panel is expected to vote on whether seven types of peptides should be sold as compounded medications.
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results